How venture capital shapes emerging bio-clusters - A cross-country comparison

European Planning Studies

Volumn 16, Issue 3, 2008, Pages 441-463

  Valentin, Finn ^a   Jensen, Rasmus Lund ^a   Dahlgren, Henrich ^a  

^a Department of International Economics and Management   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CAPITAL; DRUG; FIRM OWNERSHIP; INDUSTRIAL TECHNOLOGY; REGRESSION ANALYSIS;

DENMARK; EURASIA; EUROPE; NORTHERN EUROPE; SCANDINAVIA; SWEDEN;

EID: 40749118587     PISSN: 09654313     EISSN: 14695944     Source Type: Journal    
DOI: 10.1080/09654310801920631     Document Type: Article

References (43)

1. Audretsch, D. B. (2001) The role of small firms in U.S. biotechnology clusters. Small Business Economics, 17:1, pp. 3-15.
2. Avnimelech, G. and Teubal, M. (2006) Creating venture capital industries that co-evolve with high tech: Insights from an extended industry life cycle perspective of the Israeli experience. Research Policy, 35:10, pp. 1477-1498.
3. Backlund, A., Häggblad, H., Markusson, N., Norgren, L. and Sandström, A. (2001) The Swedish Biotechnology Innovation System, Vinnova, Stockholm
4. Baum, J. A. C. and Silverman, B. S. (2004) Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startups. Journal of Business Venturing, 19:3, pp. 411-436.
5. Bisgaard, T. and Rosted, J. (2004) Et benchmark studie af venturemarkedet-hvad kan Danmark laere?, FORA, Copenhagen
6. Brink, J., McKelvey, M. and Smith, K. (2004) Conceptualising and measuring modern biotechnology. The Economic Dynamics of Modern Biotechnologies, pp. 20-40. Edward Elgar Publishing, Cheltenham
7. Champenois, C., Engel, D. and Oliver, H. (2006) What kind of German biotechnology start-ups do venture capital companies and corporate investors prefer for equity investments?. Applied Economics, 38:5, pp. 505-518.
8. Cooke, P. (2002) Biotechnology clusters as regional, sectoral innovation systems. International Regional Science Review, 25:1, pp. 8-37.
9. Cooke, P. (2006) Global bioregions: Knowledge domains, capabilities and innovation system networks. Industry and Innovation, 13:4, pp. 437-458.
10. Cooke, P. (2007) European asymmetries: A comparative analysis of German and UK biotechnology clusters. Science and Public Policy, 37:7, pp. 454-474.
11. Dahlgren, H. and Valentin, F. (2007) Shaken not Stirred - Multinational Takeovers in Sweden's Pharmaceutical Industry, Research Centre on Biotech Business, Copenhagen Business School, Copenhagen
12. Deeds, D. L., Decarolis, D. M. and Coombs, J. E. (1997) The impact of firm specific capabilities on the amount of capital raised in an initial public offering: Evidence from the biotechnology industry. Journal of Business Venturing, 12, pp. 31-46.
13. Deng, Z., Lev, B. and Narin, F. (1999) Science and technology as predictors of stock performance. Financial Analysts Journal, 55:3, pp. 20-32.
14. Ernst and Young (2006) Beyond Borders: The Global Biotechnology Report 2006, Ernst & Young, Copenhagen
15. Feldman, M. P. and Francis, J. L. (2003) Fortune favours the prepared region: The case of entrepreneurship and the capitol region biotechnology cluster. European Planning Studies, 11:7, pp. 765-788.
16. Feldman, M. P., Valentin, F. and Yoon, J. W. (2007) Organizational Legacy and Firm Performance. Paper presented at the DRUID Summer Conference Copenhagen CBS
17. Florida, R. L. and Kenney, M. (1988) Venture capital-financed innovation and technological change in the USA. Research Policy, 17, pp. 119-137.
18. Fried, V. H. and Hisrich, R. D. (1995) The venture capitalist: A relationship investor. California Management Review, 37:2, pp. 101-114.
19. Guedj, I. and Scharfstein, D. (2004) Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms, National Bureau of Economic Research, Cambridge, MA
20. Hand, J. R. M. (2005) The value relevance of financial statements in the venture capital market. The Accounting Review, 80:2, pp. 613-648.
21. Hausman, J. A. (1978) Specification Tests in Econometrics. Econometrica, 46:6, pp. 1251-1271.
22. Hellmann, T. and Puri, M. (2002) Venture capital and the professionalization of start-up firms: Empirical evidence. Journal of Finance, 57:1, p. 169.
23. Hsu, D. H. (2007) Experienced entrepreneurial founders, organizational capital, and venture capital funding. Research Policy, 36:5, pp. 722-741.
24. Isaksson, A. (1999) Effekter av venture capital i Sverige, NUTEK, Stockholm
25. Lerner, J., Shane, H. and Tsai, A. (2003) Do equity financing cycles matter? Evidence from biotechnology alliances. Journal of Financial Economics, 67:3, pp. 411-446.
26. Luukkonen, T. and Mari, M. (2007) 'Coaching' small biotech companies into success. International Journal of Biotechnology, 9:6, pp. 548-568.
27. Lynskey, M. J. (2006) Editorial: A strategy to optimise the business value of intellectual property. International Journal of Biotechnology, 8:3, pp. 146-168.
28. McKelvey, M. and Orsenigo, L. (2006) Introduction. The Economics of Biotechnology, Edward Elgar Publishing, Cheltenham
29. McMillan, G. S., Narin, F. and Deeds, D. L. (2000) An analysis of the critical role of public science in innovation: The case of biotechnology. Research Policy, 29:1, pp. 1-8.
30. Moran, N. (2006) Danish biotech outperforms its European counterparts. Nature Biotechnology, 24:12, pp. 1460-1461.
31. Muller, C. and Fujiwara, T. (2003) The entrepreneurial environment for biotech start-ups in Germany and Japan. International Journal of Biotechnology, 5:1, pp. 76-94.
32. Nicholson, S., Danzon, P. M. and McCullough, J. (2005) Biotech-pharmaceutical alliances as a signal of asset and firm quality. The Journal of Business, 78:4, pp. 1433-1464.
33. Nilsson, A. (2000) Biotechnology firms in Sweden. Small Business Economics, 17:1, pp. 93-103.
34. Organization for Economic Cooperation and Development (OECD) (2005) A Framework for Biotechnology Statistics, OECD, Paris
35. Organization for Economic Cooperation and Development (OECD) (2007) OECD Small and Medium Enterprise Companies Outlook, OECD, Paris
36. Owen-Smith, J., Riccaboni, M., Pammolli, F. and Powell, W. W. (2002) A comparison of U.S. and European university - industry relations in the life sciences. Management Science, 48:1, pp. 24-43.
37. Powell, W. W., Koput, K. W. and Bowie, J. I. (2002) The spatial clustering of science and capital: Accounting for biotech firm-venture capital relationships. Regional Studies, 36:3, pp. 291-305.
38. Stuart, T. E., Ozdemir, S. Z. and Ding, W. W. (2007) Vertical alliance networks: The case of university - biotechnology - pharmaceutical alliance chains. Research Policy, 36:4, pp. 477-498.
39. Tomas, G. B. and Jorge, N. (2007) The issue of asymmetrical growth in specialised biotechnology firms in the USA and the UK. International Journal of Biotechnology, 9:1, pp. 87-100.
40. Valentin, F. and Dahlgren, H. (2007) Alliances of Scandinavian Biotech Start-ups and their Effects on Financial Performance, Research Centre on Biotech Business, Copenhagen Business School, Copenhagen
41. Valentin, F. and Jensen, R. L. (2007) The Imprint of Founders on Biotech Firms, Research Centre on Biotech Business, Copenhagen Business School, Copenhagen
42. Valentin, F., Dahlgren, H. and Jensen, R. L. (2006) Structure, Employment and Performance in Biotech Firms - Comparison of Danish and Swedish Drug Discovery Firms, Research Centre on Biotech Business, Copenhagen Business School, Copenhagen
43. Valentin, F., Jensen, R. L. and Dahlgren, H. (2007) Research strategies in science-based start-ups. Effects on performance in Danish and Swedish biotechnology. Technology Analysis & Strategic Management, 19:3, pp. 303-328.